Tempo reale stimato
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
32,05 USD | -2,97% | -3,61% | +47,77% |
26/03 | SPYRE THERAPEUTICS, INC. : giudizio positivo da Stifel Nicolaus | ZM |
01/03 | SPYRE THERAPEUTICS, INC. : cambio di rotta da parte di Wells Fargo Securities | ZM |
Attività
Numero di dipendenti: 30
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Human Enzyme Therapeutics
100,0
%
| 2 | 100,0 % | 1 | 100,0 % | -61,96% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 2 | 100,0 % | 1 | 100,0 % | -61,96% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 22/06/23 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 01/09/23 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | 27/11 |
Chief Tech/Sci/R&D Officer | 56 | 01/02/14 | |
Mira Huyghe
PRN | Corporate Officer/Principal | - | 27/11 |
Deanna Nguyen
PRN | Corporate Officer/Principal | - | 27/11 |
Joshua Friedman
PRN | Corporate Officer/Principal | - | 27/11 |
General Counsel | 41 | 05/09/23 | |
Paul Fehlner
PRN | Corporate Officer/Principal | 61 | 27/11 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 38 | 22/06/23 |
Russell Cox
CHM | Chairman | 60 | 01/06/15 |
Jeffrey Albers
BRD | Director/Board Member | 52 | 27/11 |
Peter Harwin
BRD | Director/Board Member | 38 | 22/06/23 |
Laurie Stelzer
BRD | Director/Board Member | 56 | 27/11 |
Director/Board Member | 34 | 22/06/23 | |
Mark Mckenna
BRD | Director/Board Member | 48 | 01/02 |
Cameron Turtle
CEO | Chief Executive Officer | 34 | 22/06/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 0 | 150 000 | 0 | 0 | 87,42 % |
Azione B | 1 | 36 599 786 | 31 994 842 ( 87,42 %) | 0 | |
Azione C | 0 | 437 037 | 0 | 0 |
Coordinate società
Spyre Therapeutics, Inc.
Building 17 221 Crescent Street
02453, Waltham
+617 651 5940
http://www.aeglea.comSettore
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+47,77% | 1,33 Mrd | |
-1,27% | 102 Mrd | |
+2,94% | 96,09 Mrd | |
+2,13% | 22,28 Mrd | |
-15,52% | 21,4 Mrd | |
-8,79% | 18,14 Mrd | |
-39,98% | 17,02 Mrd | |
-13,55% | 16,09 Mrd | |
+7,05% | 13,83 Mrd | |
+35,17% | 11,97 Mrd |
- Borsa valori
- Azioni
- Azione SYRE
- Società Spyre Therapeutics, Inc.